Translate this page to:
In JoVE (1)
Other Publications (2)
Articles by John D. Powderly in JoVE
Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples
Andrew D. Hughes1, Jeff Mattison1, John D. Powderly2,3, Bryan T. Greene2,3, Michael R. King1
1Department of Biomedical Engineering, Cornell University, 2BioCytics, Inc., 3Carolina BioOncology Institute, PLLC
Circulating tumor cells are isolated from the blood of cancer patients without inflicting cellular damage. Isolation of tumor cells is accomplished using a bimolecular surface of E-selectin in addition to antibodies against epithelial markers. A nanotube coating specifically promotes cancer cell adhesion resulting in high capture purities.
Other articles by John D. Powderly on PubMed
Phase I Study of Single-agent Anti-programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jul, 2010 | Pubmed ID: 20516446
Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.
The New England Journal of Medicine. Jun, 2012 | Pubmed ID: 22658127
Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.